ArticleDiabetes, obesity & metabolism2026
Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study.Diabetes, obesity & metabolism · 2026Article
- Risk of acute pancreatitis with DPP-4 inhibitors versus SGLT2 inhibitors in medication-naïve individuals with diabetes: A target trial emulation.Diabetes, obesity & metabolism · 2026Article
- Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsTo analyse prescribing trends in antidiabetic agents stratified by background characteristics among individuals with type 2 diabetes. MATERIALS AND
methodsThis retrospective study used a large-scale database between 2015 and 2024 in Japan. Adults with type 2 diabetes receiving at least one antidiabetic prescription were included, and annual prescription rates were assessed by drug class. Trends were evaluated overall and stratified by age, sex, heart failure (HF) status, estimated glomerular filtration rate (eGFR), body mass index, haemoglobin A1c and clinical setting, because these factors are important determinants of efficacy and safety in prescribing antidiabetic agents.
resultsSodium-glucose cotransporter 2 inhibitors (SGLT2i) prescriptions showed a marked increase, rising from 4.1% (95% confidence interval [CI], 4.0%-4.2%) in 2015 to 38.9% (95% CI, 38.7%-39.0%) in 2024. Particularly high prescription rates were seen in individuals aged <65 years, with HF, eGFR <30 mL/min/1.73 m
conclusionsIn this large-scale analysis, SGLT2i use increased substantially across diverse individual traits, supporting their integration into diverse clinical contexts in real-world practice. Our findings may provide valuable insights into diabetes care in the forthcoming era of super-aged societies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.